Lung cancer in never smokers: how can we identify those at highest risk?
DAY 2
Chaired by: Professor Mat Callister (Leeds) and Dr Tanya Patrick (London)
9:00am - Integrating epidemiologic, genomic, and experimental data to outline a unifying framework for lung adenocarcinoma in never smokers
Dr Maria Theresa Landi (USA)
9:30am - Understanding and integrating environmental and inherited risk
Dr Frank McCaughan (Cambridge)
10:00am - How do we identify high risk people? Biomarkers, risk profiling and screening
Dr Hillary Robbins (Lyon)
9:00 AM
90 MINUTE SESSION
Learning objectives
- To understand the key genetic drivers of lung cancer in never-smokers, understand how these differ from smoking-related disease, and recognise the clinical implications for diagnosis and treatment pathways.
- To describe the distinctive features of the tumour micro-environment in lung cancer in never-smokers, including inflammatory pathways and immune cell interactions, and understand their implications for tumour development, progression and treatment.
- To understand current and emerging approaches to risk stratification in never-smokers, including the role of biomarkers and risk prediction models, with reference to the principles of screening, balancing benefit against harm and maximising mortality benefit.
Speakers
i
BIOGRAPHY
Professor Mat Callister is a Consultant Respiratory Physician at Leeds Teaching Hospitals, and an Honorary Professor of Respiratory Medicine at the University of Leeds. His research interests are in the early detection of lung cancer through low-dose CT screening and symptomatic detection, and smoking cessation. He has led/co-led various studies (Yorkshire Lung Screening Trial, YESS, MEDLEY, YorQuit), is a member of the NHS England Lung Cancer Screening Programme Expert Advisory Group, and is a section chair for the IARC Lung Cancer Screening Handbook currently in development.
Professor Mat Callister